Harvard Bioscience (NASDAQ:HBIO) Share Price Passes Below 200-Day Moving Average – Should You Sell?

Harvard Bioscience, Inc. (NASDAQ:HBIO)’s stock price passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $5.98 and traded as low as $5.82. Harvard Bioscience shares last traded at $6.01, with a volume of 8,953 shares changing hands.

Analyst Upgrades and Downgrades

Several analysts have issued reports on HBIO shares. Wall Street Zen downgraded shares of Harvard Bioscience from a “buy” rating to a “hold” rating in a research note on Saturday, March 21st. New Street Research set a $6.00 price target on Harvard Bioscience in a report on Friday, March 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Harvard Bioscience in a research note on Friday, March 27th. Finally, Benchmark dropped their price objective on Harvard Bioscience from $20.00 to $6.00 and set a “speculative buy” rating for the company in a report on Friday, March 13th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $6.00.

Harvard Bioscience Stock Down 2.0%

The business’s fifty day moving average is $6.09 and its two-hundred day moving average is $5.97. The company has a market cap of $26.88 million, a P/E ratio of -2.75 and a beta of 1.53. The company has a debt-to-equity ratio of 3.60, a quick ratio of 1.06 and a current ratio of 1.99.

Harvard Bioscience (NASDAQ:HBIO) last released its quarterly earnings data on Tuesday, May 12th. The medical instruments supplier reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.29. The company had revenue of $20.75 million during the quarter, compared to analysts’ expectations of $21.20 million. Harvard Bioscience had a negative net margin of 11.44% and a negative return on equity of 25.78%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of HBIO. Bank of America Corp DE raised its position in Harvard Bioscience by 44.4% during the 4th quarter. Bank of America Corp DE now owns 38,883 shares of the medical instruments supplier’s stock valued at $82,000 after purchasing an additional 11,948 shares in the last quarter. Acadian Asset Management LLC grew its position in shares of Harvard Bioscience by 7.8% during the 1st quarter. Acadian Asset Management LLC now owns 1,077,069 shares of the medical instruments supplier’s stock worth $606,000 after buying an additional 78,276 shares in the last quarter. Strs Ohio bought a new position in shares of Harvard Bioscience during the 1st quarter worth $117,000. Marshall Wace LLP bought a new position in shares of Harvard Bioscience during the 2nd quarter worth $61,000. Finally, Jane Street Group LLC increased its stake in shares of Harvard Bioscience by 491.9% during the second quarter. Jane Street Group LLC now owns 70,736 shares of the medical instruments supplier’s stock valued at $31,000 after buying an additional 58,785 shares during the period. Institutional investors own 80.87% of the company’s stock.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.

Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools.